Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells

Arturi, 2000, Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas, Eur. J. Endocrinol., 143, 623, 10.1530/eje.0.1430623 Arturi, 2001, Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors, Eur. J. Endocrinol., 145, 129, 10.1530/eje.0.1450129 Baquero, 2013, (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a snail-dependent mechanism, Cancer Lett., 335, 232, 10.1016/j.canlet.2013.02.033 Broad Institute TCGA Genome Data Analysis Center, 2015, Correlation between mRNAseq expression and clinical features, Broad Inst. MIT Harv. Bulotta, 2006, Endothelial nitric oxide synthase is segregated from caveolin-1 and localizes to the leading edge of migrating cells, Exp. Cell. Res., 312, 877, 10.1016/j.yexcr.2005.12.014 Bulotta, 2009, Basal nitric oxide release attenuates cell migration of HeLa and endothelial cells, Biochem. Biophys. Res. Commun., 386, 744, 10.1016/j.bbrc.2009.06.118 Bulotta, 2013, Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells, J. Mol. Endocrinol., 51, 181, 10.1530/JME-12-0241 Bulotta, 2016, Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine, Endocrine, 52, 214, 10.1007/s12020-015-0830-4 Carneiro, 2015, Targeted therapies in advanced differentiated thyroid cancer, Cancer Treat. Rev., 41, 690, 10.1016/j.ctrv.2015.06.002 Celano, 2015, Flavonoid fraction of Citrus reticulata juice reduces proliferation and migration of anaplastic thyroid carcinoma cells, Nutr. Cancer, 67, 1183, 10.1080/01635581.2015.1073760 da Silveira Mitteldorf, 2011, FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples, Diagn. Cytopathol., 39, 556, 10.1002/dc.21423 D’Agostino, 2012, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells, Thyroid, 22, 138, 10.1089/thy.2011.0060 Durante, 2007, BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism, J. Clin. Endocrinol. Metab., 92, 2840, 10.1210/jc.2006-2707 Fagin, 2008, Molecular pathology of thyroid cancer: diagnostic and clinical implications, Best. Pract. Res. Clin. Endocrinol. Metab., 22, 955, 10.1016/j.beem.2008.09.017 Fryknäs, 2006, Molecular markers for discrimination of benign and malignant follicular thyroid tumors, Tumour Biol., 27, 211, 10.1159/000093056 Fujarewicz, 2007, A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping, Endocr. Relat. Cancer, 14, 809, 10.1677/ERC-06-0048 Galrão, 2013, Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression, Endocrine, 43, 225, 10.1007/s12020-012-9779-8 Griffith, 2006, Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers, J. Clin. Oncol., 24, 5043, 10.1200/JCO.2006.06.7330 Hardy, 2007, Snail family transcription factors are implicated in thyroid carcinogenesis, Am. J. Pathol., 171, 1037, 10.2353/ajpath.2007.061211 Haugen, 2016, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer, Thyroid, 26, 1, 10.1089/thy.2015.0020 Huang, 2001, Gene expression in papillary thyroid carcinoma reveals highly consistent profiles, Proc. Natl. Acad. Sci. U. S. A., 98, 15044, 10.1073/pnas.251547398 Huber, 2005, Molecular requirements for epithelial-mesenchymal transition during tumor progression, Curr. Opin. Cell Biol., 17, 548, 10.1016/j.ceb.2005.08.001 Jeon, 2015, Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells, Exp. Cell. Res., 333, 116, 10.1016/j.yexcr.2015.02.019 Jung, 2015, Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis, Clin. Cancer Res., 21, 962, 10.1158/1078-0432.CCR-13-3173 Knauf, 2011, Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling, Oncogene, 30, 3153, 10.1038/onc.2011.44 Kogai, 2012, The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics, Pharmacol. Ther., 135, 355, 10.1016/j.pharmthera.2012.06.007 Lavarone, 2013, The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines, Mol. Cell. Endocrinol., 365, 1, 10.1016/j.mce.2012.08.019 Liu, 2005, 1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness, Mol. Endocrinol., 19, 2349, 10.1210/me.2005-0117 Maggisano, 2014, Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells, Endocrine, 45, 148, 10.1007/s12020-013-9972-4 Mehra, 2015, Database and registry research in thyroid cancer: striving for a new and improved national thyroid cancer database, Thyroid, 25, 157, 10.1089/thy.2014.0270 Montemayor-Garcia, 2013, The role of epithelial mesenchymal transition markers in thyroid carcinoma progression, Endocr. Pathol., 24, 206, 10.1007/s12022-013-9272-9 Nucera, 2009, Role of B-RafV600E in differentiated thyroid cancer and preclinical validation of compounds against B-RafV600E, Biochim. Biophys. Acta, 1795, 152 Nucera, 2011, BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression, Cancer Res., 71, 2417, 10.1158/0008-5472.CAN-10-3844 Pal, 2013, Extracellular matrix protein fibronectin induces matrix metalloproteinases in human prostate adenocarcinoma cells PC-3, Cell Commun. Adhes., 20, 105, 10.3109/15419061.2013.833193 Passon, 2015, Somatic amplifications and deletions in genome of papillary thyroid carcinomas, Endocrine, 50, 453, 10.1007/s12020-015-0592-z Prasad, 2005, Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors, Mod. Pathol., 18, 48, 10.1038/modpathol.3800235 Puppin, 2008, High periostin expression correlates with aggressiveness in papillary thyroid carcinomas, J. Endocrinol., 197, 401, 10.1677/JOE-07-0618 Puxeddu, 2008, Clinical implications of BRAF mutation in thyroid carcinoma, Trends Endocrinol. Metab., 19, 138, 10.1016/j.tem.2007.12.003 Riesco-Eizaguirre, 2009, The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer, Cancer Res., 69, 8317, 10.1158/0008-5472.CAN-09-1248 Rodrigues, 2007, Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas, Oncol. Rep., 18, 917 Rosignolo, 2015, Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression, J. Endocrinol. Invest., 38, 1283, 10.1007/s40618-015-0309-4 Russo, 2011, Epigenetics of thyroid cancer and novel therapeutic targets, J. Mol. Endocrinol., 46, R73, 10.1530/JME-10-0150 Russo, 2013, Targeting histone deacetylase in thyroid cancer, Expert Opin. Ther. Targets, 17, 179, 10.1517/14728222.2013.740013 Schlumberger, 2007, Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients, Nat. Clin. Pract. Endocrinol. Metab., 3, 260, 10.1038/ncpendmet0449 Schweppe, 2008, Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification, J. Clin. Endocrinol. Metab., 93, 4331, 10.1210/jc.2008-1102 Spitzweg, 2014, Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets, Lancet Diabetes Endocrinol., 2, 830, 10.1016/S2213-8587(14)70051-8 Sponziello, 2013, Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer, Endocrinology, 154, 3043, 10.1210/en.2013-1028 Sponziello, 2015, PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells, Endocrine, 50, 434, 10.1007/s12020-015-0586-x Stanisavljevic, 2011, The p65 subunit of NF-κB and PARP1 assist Snail1 in activating fibronectin transcription, J. Cell Sci., 124, 4161, 10.1242/jcs.078824 Thiery, 2006, Complex networks orchestrate epithelial-mesenchymal transitions, Nat. Rev. Mol. Cell Biol., 7, 131, 10.1038/nrm1835 Udelsman, 2014, The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds, Thyroid, 24, 472, 10.1089/thy.2013.0257 Vasko, 2007, Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion, Proc. Natl. Acad. Sci. U. S. A., 104, 2803, 10.1073/pnas.0610733104 Xing, 2011, The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204), Biochem. Biophys. Res. Commun., 404, 958, 10.1016/j.bbrc.2010.12.088 Xing, 2013, Molecular pathogenesis and mechanisms of thyroid cancer, Nat. Rev. Cancer, 13, 184, 10.1038/nrc3431 Yousif, 2014, Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway, Cell Biol. Int., 38, 85, 10.1002/cbin.10184 Zhang, 2014, Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis, Life Sci., 118, 39, 10.1016/j.lfs.2014.09.025